Replimune Group - REPL Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings or view top-rated stocks.

7 brokerages have issued 12 month price objectives for Replimune Group's stock. Their REPL share price forecasts range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.86 in the next year. This suggests a possible upside of 175.8% from the stock's current price.
View analysts price targets for REPL or view top-rated stocks among Wall Street analysts.

Replimune Group's stock was trading at $27.20 at the beginning of the year. Since then, REPL shares have decreased by 30.9% and is now trading at $18.80.
View the best growth stocks for 2023 here.

Replimune Group saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 2,800,000 shares, an increase of 97.2% from the February 13th total of 1,420,000 shares. Based on an average daily trading volume, of 582,700 shares, the days-to-cover ratio is currently 4.8 days. Currently, 7.2% of the company's stock are sold short.
View Replimune Group's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 18th 2023.
View our REPL earnings forecast.

Replimune Group, Inc. (NASDAQ:REPL) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.05.

ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA Healthcare Momentum ETF (PTH), Harbor Disruptive Innovation ETF (INNO), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and SPDR S&P Biotech ETF (XBI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Replimune Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (10.18%), Omega Fund Management LLC (6.76%), Atlas Venture Life Science Advisors LLC (4.22%), T. Rowe Price Investment Management Inc. (2.18%), Emerald Advisers LLC (2.38%) and Frazier Life Sciences Management L.P. (1.87%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends.

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REPL stock can currently be purchased for approximately $18.80.

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.07 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis.

The company employs 152 workers across the globe.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.